New pancreatic cancer pill could reshape treatment as early trial results stun researchers
Monday, May 18th 2026, 11:00:13 am
article
Daraxonrasib, a new pancreatic cancer drug targeting RAS mutations found in over 90% of cases, showed promising results in the first human trial led by the Dana-Farber Cancer Institute.
Breaking
https://thefederalist.com/2026/05/18/how-the-ccp-uses-birthplace-citizenship-and-surrogacy-to-manufacture-americans/?utm_source=rss&utm_medium=rss&utm_campaign=how-the-ccp-uses-birthplace-citizenship-...
https://thefederalist.com/2026/05/18/of-course-our-immigration-system-should-discriminate-against-bad-immigrants/?utm_source=rss&utm_medium=rss&utm_campaign=of-course-our-immigration-system-should-dis...
https://thefederalist.com/2026/05/18/georgia-investigators-killed-2020-election-probe-at-kemps-request-unsealed-testimony-claims/?utm_source=rss&utm_medium=rss&utm_campaign=georgia-investigators-kille...
